Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 ...
#benzai #BMEA #Equities #News #Type #2 #Diabetes #Health […]
[Original post on benzinga.com]